Logo image of KLRS

KALARIS THERAPEUTICS INC (KLRS) Stock Fundamental Analysis

NASDAQ:KLRS - Nasdaq - US4829291065 - Common Stock - Currency: USD

3.3  +0.19 (+6.11%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to KLRS. KLRS was compared to 558 industry peers in the Biotechnology industry. While KLRS has a great health rating, there are worries on its profitability. KLRS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KLRS had negative earnings in the past year.
In the past year KLRS has reported a negative cash flow from operations.
In the past 5 years KLRS always reported negative net income.
KLRS had a negative operating cash flow in each of the past 5 years.
KLRS Yearly Net Income VS EBIT VS OCF VS FCFKLRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

The Return On Assets of KLRS (-37.10%) is comparable to the rest of the industry.
KLRS's Return On Equity of -59.70% is fine compared to the rest of the industry. KLRS outperforms 60.39% of its industry peers.
Industry RankSector Rank
ROA -37.1%
ROE -59.7%
ROIC N/A
ROA(3y)-69.98%
ROA(5y)-57.75%
ROE(3y)-85.83%
ROE(5y)-70.72%
ROIC(3y)N/A
ROIC(5y)N/A
KLRS Yearly ROA, ROE, ROICKLRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KLRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KLRS Yearly Profit, Operating, Gross MarginsKLRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for KLRS has been reduced compared to 1 year ago.
The number of shares outstanding for KLRS has been reduced compared to 5 years ago.
There is no outstanding debt for KLRS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KLRS Yearly Shares OutstandingKLRS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
KLRS Yearly Total Debt VS Total AssetsKLRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -1.12, we must say that KLRS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of KLRS (-1.12) is comparable to the rest of the industry.
KLRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.12
ROIC/WACCN/A
WACCN/A
KLRS Yearly LT Debt VS Equity VS FCFKLRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 14.29 indicates that KLRS has no problem at all paying its short term obligations.
The Current ratio of KLRS (14.29) is better than 86.38% of its industry peers.
A Quick Ratio of 14.29 indicates that KLRS has no problem at all paying its short term obligations.
KLRS's Quick ratio of 14.29 is amongst the best of the industry. KLRS outperforms 86.38% of its industry peers.
Industry RankSector Rank
Current Ratio 14.29
Quick Ratio 14.29
KLRS Yearly Current Assets VS Current LiabilitesKLRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for KLRS have decreased strongly by -270.89% in the last year.
EPS 1Y (TTM)-270.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KLRS will show a very negative growth in Earnings Per Share. The EPS will decrease by -114.02% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-291.61%
EPS Next 2Y-114.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KLRS Yearly Revenue VS EstimatesKLRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2027 20M 40M 60M 80M
KLRS Yearly EPS VS EstimatesKLRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KLRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KLRS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KLRS Price Earnings VS Forward Price EarningsKLRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KLRS Per share dataKLRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

KLRS's earnings are expected to decrease with -114.02% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-114.02%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KLRS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KALARIS THERAPEUTICS INC

NASDAQ:KLRS (6/6/2025, 8:03:36 PM)

3.3

+0.19 (+6.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-07 2025-08-07
Inst Owners42.88%
Inst Owner ChangeN/A
Ins Owners6.37%
Ins Owner Change99.63%
Market Cap61.71M
Analysts87.5
Price Target20.4 (518.18%)
Short Float %0.44%
Short Ratio1.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-112.96%
EPS NQ rev (3m)N/A
EPS NY rev (1m)16.88%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)-6.13
EYN/A
EPS(NY)-2.32
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0
BVpS3.42
TBVpS3.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.1%
ROE -59.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.98%
ROA(5y)-57.75%
ROE(3y)-85.83%
ROE(5y)-70.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.29
Quick Ratio 14.29
Altman-Z -1.12
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-270.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.86%
EPS Next Y-291.61%
EPS Next 2Y-114.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y72.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.38%
OCF growth 3YN/A
OCF growth 5YN/A